Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 3 |
2019 | 4 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.
Arthritis Rheumatol. 2019 Jul;71(7):1056-1069. doi: 10.1002/art.40840. Epub 2019 Jun 7.
Arthritis Rheumatol. 2019.
PMID: 30653843
Free article.
Clinical Trial.
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM.
Hyams JS, et al.
Aliment Pharmacol Ther. 2019 Jan;49(2):155-164. doi: 10.1111/apt.15054. Epub 2018 Dec 2.
Aliment Pharmacol Ther. 2019.
PMID: 30506693
Clinical Trial.
Item in Clipboard
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
Jemec GBE, et al.
Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.
Br J Dermatol. 2019.
PMID: 30916379
Free PMC article.
Clinical Trial.
Item in Clipboard
ZFYVE21 is a complement-induced Rab5 effector that activates non-canonical NF-κB via phosphoinosotide remodeling of endosomes.
Fang C, Manes TD, Liu L, Liu K, Qin L, Li G, Tobiasova Z, Kirkiles-Smith NC, Patel M, Merola J, Fu W, Liu R, Xie C, Tietjen GT, Nigrovic PA, Tellides G, Pober JS, Jane-Wit D.
Fang C, et al.
Nat Commun. 2019 May 21;10(1):2247. doi: 10.1038/s41467-019-10041-2.
Nat Commun. 2019.
PMID: 31113953
Free PMC article.
Item in Clipboard
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV.
Martinello M, et al.
J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8.
J Viral Hepat. 2018.
PMID: 29660224
Clinical Trial.
Item in Clipboard
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N.
Waked I, et al.
J Med Virol. 2018 Nov;90(11):1739-1744. doi: 10.1002/jmv.25243. Epub 2018 Jul 16.
J Med Virol. 2018.
PMID: 29900553
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite